Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Up 79.1% in July

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 56,620 shares, an increase of 79.1% from the June 30th total of 31,620 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 88,554 shares, the short-interest ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Get Our Latest Report on LZAGY

Lonza Group Price Performance

Shares of LZAGY stock traded up $1.05 on Thursday, reaching $70.93. 16,630 shares of the company’s stock traded hands, compared to its average volume of 79,677. Lonza Group has a 12-month low of $58.53 and a 12-month high of $73.85. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24. The business’s 50 day moving average price is $65.99 and its two-hundred day moving average price is $65.61.

Lonza Group Company Profile

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Featured Stories

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.